Rolf Muller, Ph.D.
Chief Executive Officer
Rolf Muller is a biotechnology leader combining science and business knowledge to build and grow successful technology companies that further healthcare and the field of personalized medicine. He has structured and guided highly efficient multi-disciplinary research and commercial teams through funding, to product development, and successful product launch into global markets. Prior to joining BioFluidica he was the Founder and President of Biomatrica, which he developed from an idea to be a global leader in biopreservation technologies for diagnostic and health care companies. Over the last 16 years he has been involved in analyzing markets and developing strategies to position biotechnologies to maximize value. He has interacted with most of the major pharma and biotechnology companies to obtain funded development contracts, joint projects, and partnerships. In addition to raising successfully capital from investors he also raised non-dilutive capital from CDC, NCI, NIH, DARPA, In-Q-Tel and DOD. He obtained his Ph.D. in biochemistry from the Pasteur Institute in Paris France.
Steven A. Soper, Ph.D.
Cofounder and Chief Technology Officer
Dr. Steven A. Soper founded Biofluidica in order to develop new technologies to be used in the medical diagnostic, pathogen detection, and personalized medicine spaces. He is a worldwide recognized pioneer in the development of diagnostic platforms with over 12 years of experiences in the CTC research area along with being the author of five patents currently licensed by BioFluidica. He has over 310 peer-reviewed publications with an h-index of 56. In addition, he has generated over $60M in competitive research funding over his career with most of this funding focused on developing new technologies for in vitro diagnostics. Dr. Soper is currently a Professor in Biomedical Engineering and Chemistry at UNC-CH. He is also Director of a new Center on the UNC-CH campus; Center for BioModular Multi-scale Systems for Precision Medicine, which is focused on developing new tools for the molecular analysis of circulating biomarkers.
Judy Muller-Cohn, Ph.D
Chief Operating Officer
Judy Muller-Cohn, Ph.D. is a biotechnology leader moving scientific ideas to commercial products. She manages operations at BioFluidica overseeing commercial development of the company’s ground breaking technology to serve the growing need of the cancer diagnostic market. Previously, she founded, and for ten years was CEO, of a successful biotechnology company from idea to financing, product development, patenting, grant management, human resources, and business development. She also serves on the boards of for-profit and non-profit organizations. Judy earned a Ph.D. in microbial biochemistry from Universite Paris VI and conducted her research at the Pasteur Institute in Paris, France.
Mateusz Hupert, Ph.D.
Director of Instrumentation & Diagnostic Development
Dr. Hupert has 10 years of experience in the area of microfabrication, in particular the area of fabrication structures in plastics using replication-based technologies, such as hot embossing and injection molding. He is currently the Director of Microfabrication Technology at BioFluidica and is the PI on the SBIR grants that BioFluidica currently holds. In addition, he has been instrumental in the design and the building of the instrumentation that has evolved as a result of our SBIR grants including instruments for fluorescence imaging of selected CTCs for immunophenotyping. Dr. Hupert also has experiences in fluidic mechanics and electrochemistry as part of his graduate studies.
Bryan Greene, Ph.D.
Director of Scientific and Medical Affairs
Dr. Bryan Greene is currently working with BioFluidica where he will be helping with clinical development of the BioFluidica platform. He previously was Director of Regulatory Affairs of Carolina Biooncology Institute, PLLC and Chief Scientific Officer of Biocytics, Inc. Dr. Greene has almost 10 years of experience in the molecular diagnostics space, including using circulating tumor cells in development of companion diagnostics. He received his Ph.D. in Cancer Biology from the Wake Forest University School of Medicine.
C.J. Jiang, Ph.D.
Senior Vice-President Clinical Development
Dr. Jiang joined BioFluidica in early 2014 to lead the company’s engineering and advanced system development effort. He brings over 20 years of diagnostic imaging, software engineering, and product development experience, and has worked at several start-up companies bringing regulated products to market. Dr. Jiang received his Ph.D. degree from Cornell University and has worked at research institutions and medical device companies with foci in Biomedical Engineering, including circulating biomarkers and digital pathology.